Skip to content

Voyager Therapeutics, Inc.

VYGR

CIK 0001640266

← back to feed
Revenue (TTM)
$27.63M
−49.5% YoY Q1 Apr 2026
Net Income (TTM)
−$120.23M
−84.2% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.04
−80.5% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-478.4%
Q1 Apr 2026
Net Margin
-435.1%
Q1 Apr 2026
Free Cash Flow (TTM)
$107.7M
Q1 Apr 2026
Cash
$43.31M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
60.42M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings